• ABCL

Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth

AbCellera discussed its transition to a clinical-stage biotech firm, upcoming CTA filings, financial results, and strategic focus during the Q3 2024 Earnings Call.